Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, today announced that company management will present at the following investor conferences:

• 32^nd Annual Oppenheimer Healthcare Conference
  • Tuesday, March 15^th, 2022 at 1:20 pm ET

• Stifel 2022 CNS Days
  • Monday, March 28^th, 2022 at 8:45 AM ET

About Pipeline Therapeutics

Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address CNS and neuro-otology conditions, and its flagship program, PIPE-307, has completed a Phase 1 clinical trial in healthy volunteers to support future studies in MS patients. For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005789/en/